Evelyn Krohmer

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Antiretroviral Therapy

Respiratory Syndrome Coronavirus

Top Venues

Clinical pharmacokinetics

Cardiovascular drugs and therapy

The Annals of pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics 63 (4) (2024)
Evelyn Krohmer, Walter E Haefeli
Comment on: Increased Theophylline Plasma Concentrations in a Patient With COVID-19. The Annals of pharmacotherapy (2024)
Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics 63 (4) (2024)
Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics 63 (4) (2024)
Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics 63 (4) (2024)
Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics (2024)
Evelyn Krohmer, Brit Silja Rohr, Felicitas Stoll, Katja S Gümüs, Mariano Bergamino, Gerd Mikus, Max Sauter, Juergen Burhenne, Johanna Weiss, Andreas Daniel Meid, David Czock, Antje Blank, Walter Emil Haefeli
Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin. Cardiovascular drugs and therapy (2023)